title: Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors.
abstract: Infectious complications are a major cause of morbidity and mortality in patients with hemato-oncological diseases. Although disease-related immunosuppression represents one factor, aggressive treatment regimens, such as chemotherapy, stem cell transplantation, or antibody treatment, account for a large proportion of infectious side effects. With the advent of targeted therapies affecting specific kinases in malignant diseases, the outcome of patients has further improved. Nonetheless, dependent on the specific pathway targeted or off-target activity of the kinase inhibitor, therapy-associated infectious complications may occur. We review the most common and approved kinase inhibitors targeting a variety of hemato-oncological malignancies for their immunosuppressive potential and evaluate their risk of infectious side effects based on preclinical evidence and clinical data in order to raise awareness of the potential risks involved.
authors.affiliation: Department of Hematology and Oncology, Mannheim University Hospital, University of Heidelberg, Mannheim, Germany.
authors.forename: Mark
authors.initials: M
authors.lastname: Reinwald
authors.affiliation: Department of Hematology and Oncology, Mannheim University Hospital, University of Heidelberg, Mannheim, Germany.
authors.forename: Tobias
authors.initials: T
authors.lastname: Boch
authors.affiliation: Department of Hematology and Oncology, Mannheim University Hospital, University of Heidelberg, Mannheim, Germany.
authors.forename: Wolf-Karsten
authors.initials: WK
authors.lastname: Hofmann
authors.affiliation: Department of Hematology and Oncology, Mannheim University Hospital, University of Heidelberg, Mannheim, Germany.
authors.forename: Dieter
authors.initials: D
authors.lastname: Buchheidt
keywords: BCR signaling; BCR-ABL; BRAF; EGFR; JAK; TKI; VEGF; infections; infectious complications; kinase inhibitors; mTOR; targeted therapy